Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 12/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 9/20 | 0.51 |
| ▸ | LYN | P07948 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 5/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399915 | 0.87 | AURKA (0.55) | PRKCQPRKCDLYNAURKA | |
| SCHEMBL13399893 | 0.84 | CHEK1 (0.44) | PRKCQPRKCDLYNAURKACHEK1 | |
| SCHEMBL13399914 | 0.81 | AURKA (0.47) | AURKACHEK1 | |
| SCHEMBL13399908 | 0.81 | AURKA (0.66) | AURKACHEK1 | |
| SCHEMBL13399966 | 0.80 | AURKA (0.49) | AURKACHEK1IMPDH2 | |
| SCHEMBL13399885 | 0.79 | AURKA (0.50) | AURKACHEK1IMPDH2 | |
| SCHEMBL13399961 | 0.79 | MAPT (0.51) | PRKCDAURKACHEK1ALDH1A1 | |
| SCHEMBL13399882 | 0.78 | AURKA (0.66) | AURKA | |
| SCHEMBL13399919 | 0.77 | AURKA (0.60) | PRKCQPRKCDAURKACHEK1 | |
| SCHEMBL13399970 | 0.77 | MAP2K1 (0.57) | AURKAALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| EP-2331530-B1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (CN) | 2013-08-21 | — | — | EP | disclosed |
| WO-2010036629-A2 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, AURKB | PRKCQ 99/4885PRKCD 169/4885LYN 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.